Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia

Pathology International

Volumn 48, Issue 8, 1998, Pages 580-585

  Sano, Takaaki ^a   Oyama, Tetsunari ^a   Kashiwabara, Kenji ^a   Fukuda, Toshio ^a   Nakajima, Takashi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Cervical intraepithelial neoplasia; Immunohistochemistry; Invasive cervical cancer; P16; Retinoblastoma (Rb) protein

Indexed keywords

PROTEIN P16; RETINOBLASTOMA PROTEIN;

ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

EID: 0031716133     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1998.tb03954.x     Document Type: Article

References (25)

1. zur Hausen H. Papillomavirus infections: A major cause of human cancers. Biochim. Biophys. Acta 1996; 1288: F55-F78.
2. Amortegui AJ, Meyer MP, Elborne VL, Amin RM. P53, retinoblastoma gene product, and cyclin protein expression in human papillomavirus virus DNA-positive cervical intraepithelial neoplasia and invasive cancer. Mod. Pathol. 1995; 8: 907-912.
3. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumor-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995; 375: 506-510.
4. Sherr CJ. Cancer cell cycles. Science 1996; 274; 1672-1677.
5. Shapiro GI, Edwards CD, Kobzik L et al. Reciprocal Rb inactivation and p16 expression in primary lung cancers and cell lines. Cancer Res. 1995; 55; 505-509.
6. Sakaguchi M, Fujii Y, Hirabayashi H et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers. Int. J. Cancer 1996; 65; 442-445.
7. Kratzke RA, Greatens TM, Rubins JB et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res. 1996; 56: 3415-3420.
8. Kinoshita I, Dosaka-Akita H, Mishima T et al. Altered p16 and retinoblastoma protein status in non-small cell lung cancer. Cancer Res. 1996; 56: 5557-5562.
9. Piccinin S, Doglioni C, Maestro R et al. P16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int. J. Cancer 1997; 74: 26-30.
10. Papadimitrakopoulou V, Izzo J, Lippman SM et al. Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 1997; 14: 1799-1803.
11. Reed AL, Califano J, Cairns P et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 1996; 56: 3630-3633.
12. Geradts J, Wilson PA. High frequency of aberrant p16 INK4a expression in human breast cancer. Am. J. Pathol. 1996; 149: 15-20.
13. Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16 in archival human solid tumors: Correlation with retinoblastoma protein expression. Cancer Res. 1995; 55: 6006-6011.
14. Wadayama B, Toguchida J, Shimizu T et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res. 1994; 54: 3042-3048.
15. Herman JG, Merlo A, Mao L et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995; 55: 4525-4530.
16. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN. Molecular genetic correlates of p16, cdk4 and pRb immunohistochemistry in glioblastomas. J. Neuropathol. Exp. Neurol. 1998; 57: 122-130.
17. Dong Y, Walsh MD, McGuckin MA et al. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16 in ovarian cancer is associated with progression and unfavorable prognosis. Int. J. Cancer 1997; 74: 57-63.
18. Chang TG, Wang J, Chen LW et al. Loss of expression of the p16 gene is frequent in malignant skin tumors. Biochem. Biophys. Res. Commun. 1997; 230: 85-88.
19. Choo K-B, Chang KY. Absence of mutation in the p53 and the retinoblastoma genes in primary cervical carcinomas. Virology 1993; 193: 1042-1046.
20. Kelley MJ, Otterson GA, Kaye FJ, Popescue NC, Johnson BE, Dipaolo JA. CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. Int. J. Cancer 1995; 63: 226-230.
21. Hirama T, Miller CW, Wilczynski SP, Koeffler HP. P16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines. Mod. Pathol. 1996; 9: 26-31.
22. Khleif SN, DeGregori J, Yee CL et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc. Natl Acad. Sci. USA 1996; 93: 4350-4354.
23. Nakao Y, Yang X, Yokoyama M et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br. J. Cancer 1997; 75: 1410-1416.
24. Kurman RJ, Norris HJ, Wilkinson EJ. Tumors of the cervix, vagina, and vulva. In: Rosai J, Sobin LH, eds. Atlas of Tumor Pathology, Fascicle 4, Series 3. The Armed Forces Institute of Pathology, Washington DC, 1992; 40-44.
25. Weir MM, Bell DA, Young RH. Transitional cell metaplasia of the uterine cervix and vagina: An underrecognized lesion that may be confused with high-grade dysplasia. Am. J. Surg. Pathol. 1997; 21: 510-517.